De Brauw advised BC Partners, together with Kirkland & Ellis, on the sale of Pharmathen, a leading European pharmaceutical company, to Partners Group. The transaction values Pharmathen at approximately EUR 1.6 billion.
Founded in 1969, Pharmathen is the leading European drug delivery technology company. With a highly differentiated business model and strong management team, the company is a specialist in the development of "sustained release" technologies, with best-in-class R&D capabilities. The company is a global leader in complex long lasting injectables and has also established a long-acting therapeutic technologies platform which will fuel growth for many years. Partners Group will work with Pharmathen on initiatives to scale the business in Europe and globally, and supporting the company to accelerate its expansion in the US. The transaction is expected to close by the end of 2021.
Team
Yi Duan
Partner
Annelieke Anbeek
Senior Associate
Willemijn van der Storm
Associate
Lenina Broers
Associate
Esther Huijzer
Senior Associate
Abe Stegenga
Senior Associate
Myrthe Voortman – van der Klei
Senior Associate
David Mees
Senior Associate